Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of November 2019, with a specific reporting date of November 12, 2019. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) under the Company's Share Reward Plan.
Key Financial Metrics
This filing does not contain consolidated financial statements, revenue, profit, cash flow, or debt metrics. It exclusively reports on specific share acquisition transactions.
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Price: £17.2659 per share.
- Transaction Volume: Individual acquisitions ranged from 14 to 16 shares per executive.
- Transaction Date: November 11, 2019.
- Exchange: London Stock Exchange (XLON).
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy. It documents routine compliance notifications for share acquisitions by senior executives.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transactions were executed under the Company's Share Reward Plan, consisting of partnership shares and matching shares.
Investor Verification Checklist
- Verify the total number of shares acquired by the listed executives (Ms E Walmsley, Mr R Connor, Ms D Conrad, Mr N Hirons, Ms S Jackson, Mr D Jackson, Mr D Redfern, Mr R Simard, Mr P Thomson, Ms V Whyte) against the company's broader equity compensation disclosures.
- Confirm the market price of GSK ordinary shares on November 11, 2019, to validate the transaction price of £17.2659.
- Review the specific terms of the GSK Share Reward Plan to understand the vesting schedule and conditions for the "partnership" and "matching" shares acquired.
- Note that this filing is a regulatory notification of insider activity and does not reflect the company's overall financial performance for the period.